Brainsway Ltd - ADR
BWAY
Get informed when a big investor buys or sells
+ FollowMarket Cap$616.98M
Close$
$3.68
77.7% downside
Current Fair Value
77.7% downsideOvervalued by 77.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $616.98 Million |
|---|---|
| Enterprise Value | $576.74 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.4 |
| Beta | 0.15 |
| Outstanding Shares | 19,083,333 |
Return
| Return on Equity | 12.46% |
|---|---|
| Return on Assets | 8.07% |
| Return on Invested Capital | 5.95% |
Valuation & Multiples
| P/E Ratio | 67.71 |
|---|---|
| PEG | 63.36 |
| Price to Sales | 5.5 |
| Price to Book Ratio | 5.5 |
| Enterprise Value to Revenue | 9.53 |
| Enterprise Value to EBIT | 103.76 |
| Enterprise Value to Net Income | 61 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$0.05
Average shareholder expectationRevenue Estimate
$14.63 M
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$0.10
Average shareholder expectationRevenue Estimate
$16.53 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 61.38%▲ 30.23% |
|---|---|
| Total Invested | $155.63M▲ 38.24% |
| Investors Holding | 56▲ 12.00% |
ESG Score
No data
About Brainsway Ltd.
CEO: Christopher von Jako Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the tr...